Moderna

Since AIDS was first identified, over 36 million deaths have been attributed to it worldwide.

For Moderna, effectiveness against hospitalization was 90-95% up to 9 weeks after the booster.

Bourla along with Moderna CEO Stéphane Bancel said last week that they are preparing a booster that will treat the newly-introduced Omicron variant.

The CEOs of Pfizer and Moderna say they are preparing a booster targeting Omicron. Pfizer CEO Albert Bourla is still unsure if there is a need for the fourth booster.

Receiving the COVID-19 vaccine lengthens the menstrual cycle - not bleeding - by less than a day, though it seems to be temporary, is considered a normal variation and is not dangerous.

“I think we are in a revolution that no one believed would happen.”

Moderna hopes to start clinical trials early next year on a vaccine to protect against the fast-spreading Omicron variant.

This data, though limited, puts Moderna ahead of other drugmakers, including rival Pfizer Inc, that are also testing their flu vaccine based on messenger RNA.

"There is no world, I think, where (the effectiveness) is the same level we had with Delta," said the CEO of Moderna.